Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04787848 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Jul 30, 2026 → May 30, 2027
See other at-risk trials from Florida International University

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jul 30, 2026 to May 30, 2027v7
  2. Notable Primary completion date: Nov 30, 2025 to Jul 30, 2026
    • Study completion date: Dec 30, 2025 to Jul 30, 2026
    v6
  3. Notable Lead sponsor: University of Alabama at Birmingham to Florida International University
    • Primary completion date: Jun 30, 2025 to Nov 30, 2025
    • Study site revised
    v5
  4. Notable Primary completion date: Jun 30, 2024 to Jun 30, 2025
    • Study completion date: Dec 30, 2024 to Dec 30, 2025
    v4
  5. Minor Re-verified, no change to tracked fieldsv3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 1, 2021 to Nov 15, 2021
    v2
  7. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To determine if decreased production or release of endogenous opioid peptides by peripheral immune cells contributes to hypersensitivity in people with HIV
Trial Details
NCT Number NCT04787848
Lead Sponsor Florida International University
Conditions
(from sponsor)
Chronic Widespread Pain
Related terms Chronic Pain
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov